Daily digest

What's trending, October 4, 2026

In the news

AA: Pulmonary aspiration, regurgitation under anesthesia more likely with GLP-1 RAs

Medical Xpress, carrying a HealthDay report, covers a UK national prospective observational cohort study in Anaesthesia of 47,039 adults at 119 sites undergoing anesthesia. Of these, 2.9% reported taking GLP-1 receptor agonists. Pulmonary aspiration and/or regurgitation occurred in 1.41% of that group versus 0.12% of others (odds ratio, 11.39), most often during emergence from anesthesia. Perioperative management varied, and the authors call for further prospective studies.

Why it matters: Relevant to adults using GLP-1 medicines who are considering surgery, and to the anesthesiologists, surgeons and referring clinicians involved in their perioperative care.

medicalxpress.com · October 4, 2026

Our summary →
In the news

Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial

ScienceAlert reports on a phase 3 trial in The New England Journal of Medicine of retatrutide, an experimental weekly injection, in 2,339 adults with obesity but without diabetes. At 12 milligrams, average weight loss was 25 percent after 80 weeks versus 3.9 percent with placebo; knee pain and sleep apnea events also fell more. Nausea was common. Eli Lilly funded the study, which did not compare it with existing drugs.

Why it matters: Relevant to Maryland adults with obesity but without diabetes who are exploring medical weight loss, including those with knee osteoarthritis or sleep apnea, and to clinicians who refer them.

yahoo.com · October 4, 2026

Our summary →
In the news

Menopause is a major health milestone, yet health records barely track it—new research

Medical Xpress republishes a piece from The Conversation by researchers who, in an observational review, examined electronic health records of almost 240,000 women in the NIH's All of Us Research Program. Only 12% of records mentioned menopause, though more than half the women reported the transition in surveys. Age at menopause and symptoms were also largely missing. The team is developing a short check-in questionnaire for patients.

Why it matters: Relevant to women in midlife and to referring clinicians who document reproductive health details in patients' electronic health records.

medicalxpress.com · October 4, 2026

Our summary →
In the news

'Perimenopause cost me my job and family life'

BBC reports, via Yahoo, one woman's personal account: Sally Williams spent almost 11 months in hospital across eight admissions during three years of deteriorating mental health, lost her finance job and was separated from her teenage son. Doctors initially thought she had depression; she later self-diagnosed perimenopause and credits HRT, while noting it may not suit everyone. She will speak at Worcester's Meno Fest on 7 October.

Why it matters: Relevant to Maryland adults approaching midlife who are weighing preventive or hormonal care, and to clinicians who see patients with mood changes in those years.

yahoo.com · October 4, 2026

Our summary →
In the news

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

CNBC reports that Eli Lilly and Novo are developing amylin-targeting obesity drugs to complement GLP-1 medicines. In a relatively small Phase 2 trial in patients with obesity and Type 2 diabetes, the highest-dose combination of Lilly's experimental eloralintide with tirzepatide produced 23.3% average weight loss at 48 weeks versus 14.8% on high-dose tirzepatide alone, though 10.8% to 27% stopped due to side effects. Phase 3 trials are needed.

Why it matters: Relevant to Maryland adults living with obesity and Type 2 diabetes who follow medical weight loss research, and to the clinicians who refer them for metabolic care.

cnbc.com · October 4, 2026

Our summary →
In the news

GLP-1 drugs like Ozempic linked to alarming side effect on nails

Newsweek reports on a cross-sectional, self-reported study presented at EADV in Vienna comparing 575 GLP-1 receptor users with 1,329 people with Type 2 diabetes who had never taken the drugs. Nail detachment was reported by 39 percent of users versus 9 percent of controls, and hair loss by 50 percent of users. Associations weakened after adjusting for skin conditions and nutritional deficiencies; authors say causation cannot be inferred.

Why it matters: Relevant to Maryland adults using or considering GLP-1 medications for weight loss or diabetes, and to clinicians who prescribe them or see patients with nail or hair concerns.

newsweek.com · October 4, 2026

Our summary →
In the news

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

News-Medical reports on a retrospective, real-world study of 122 adults with overweight or obesity, without type 2 diabetes, treated at two centers in Palermo, Italy. Alongside diet and activity advice, 24 weeks of tirzepatide was associated with fat mass falling 35.4% while skeletal muscle mass stayed stable. There was no control arm, and most participants were women.

Why it matters: Relevant to Maryland adults weighing medical weight loss, and to clinicians who refer them, interested in body-composition data from real-world tirzepatide care.

news-medical.net · October 4, 2026

Our summary →
In the news

Women are turning to testosterone, but what does the science actually say?

Medical Xpress republishes a Conversation explainer by Daniel Kelly on women's growing use of testosterone. A 2019 meta-analysis of 36 randomized trials supports it for distressing low sexual desire after menopause, the only evidence-backed use. An observational UK study of 510 women reported mood and cognitive improvements but cannot show causation. Long-term safety data remain limited, and the US has no approved female product.

Why it matters: Relevant to postmenopausal women in Maryland weighing menopause care options and to the gynecologists and primary care clinicians who discuss hormone therapy with them.

medicalxpress.com · October 4, 2026

Our summary →

AthleticsMD Clinical Desk

Today's front page

The newest articles and the day's news on GLP-1 & weight loss, Metabolic health, Hormones and more.

Go to the front page →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.